InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: NEW4THIS post# 75089

Thursday, 05/30/2013 11:12:45 PM

Thursday, May 30, 2013 11:12:45 PM

Post# of 158400
That article says if the FDA isn't satisfied with the toxicity and dosing then there will be a delay. But if you have been following biotech stocks as long as I have very rarely does the FDA refuse an IND application.

The only way for refusal is if the dosing is way off and the treatment is toxic. But since the company is using edothelial cells to spur the bone morrow naturally to create red blood cells I don't see how toxicity plays a role hardly at all.

It's all speculation and never a sure thing, but more likely than not they will get IND approval!

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.